Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: Pharmaceutical Drug Import to Russia (December 2018)

Friday, February 1, 2019

In 2018, Russia imported 531 bln RUB worth of ready-made pharmaceutical drugs (free circulation prices), which is in monetary terms only 1.1% higher than that in 2017, and 105.4 bln RUB worth o in-bulk pharmaceuticals, which is in monetary terms 10.3% higher than that in 2017. Despite the high dynamics of the in-bulk import, the import volume is much lower than that in 2016, when it was 111 bln RUB.

In physical terms, Russia imported 1.87 bln units of ready-made drugs, which is 7.7% lower than that in 2017, and 4 bln minimum dosage units (MDU) of in-bulk drugs, which is 5% lower than that in 2017. The total import volume in 2018 amounts to 38.5 bln MDUs, which is 5.3% lower than that in 2017.

In December 2018, the dynamics of the import of ready-made drugs in monetary terms are +5.2%, while those in physical terms are -1.8%. The dynamics of the in-bulk import are -20% in monetary terms and -27% in physical terms.

Novartis has become one of the top 10 companies importing ready-made pharmaceuticals to Russia. In 2018, it imported 41.6 bln RUB worth of ready-made drugs (customs clearance prices, VAT included.) Sanofi has the highest dynamics among the top 10 companies (+10%), in particular due to increasing its import of Clexane (a 2.3 times increase) and Aldurazyme (a 3.2 times increase.) Teva has the lowest dynamics among the top 10 companies (-10% in monetary terms), in particular for the import of Valz (-49%) and Isoprinosine (-42%.)

Among the top companies importing in-bulk drugs, Sanofi remains the absolute leader. In 2018, it imported 12.6 bln RUB worth of in-bulk pharmaceuticals, with Toujeo Solostar and Pentaxim accounting for most of the import. Merck Group has the highest dynamics in monetary terms among the top 10 importing companies, in particular due to large import volumes of Concor and Rebif. AstraZeneca has the lowest dynamics (-44%), in particular due to lower import volumes of Zoladex, Symbicort Turbuhaler, and Faslodex.

Read more about pharmaceutical drug import to Russia (November 2018 results) here: http://rncph.com/news/21_01_2019

Dynamics of import of pharmaceuticals, including homeopathic and seawater drugs, to Russia, free circulation prices including customs clearance and VAT, RUB (2014–2018)

Share: